A Multiple Dose Titration Study in Participants With Obesity or Overweight to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677
Latest Information Update: 22 Nov 2024
At a glance
- Drugs Mazdutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
Most Recent Events
- 01 Jul 2023 Status changed from active, no longer recruiting to completed.
- 15 May 2023 Planned End Date changed from 22 Dec 2023 to 21 Jun 2023.
- 15 May 2023 Planned primary completion date changed from 22 Dec 2023 to 21 Jun 2023.